Pre- and postoperative therapy with GnRH agonist for endometrial resection. A prospective, randomized study.

Sørensen SS, Colov NP, Vejerslev LO

Acta obstetricia et gynecologica Scandinavica1 Apr 1997Cited by 17 (Europe PMC)

PMID9174428DOI10.1111/j.1600-0412.1997.tb07989.xPepBankPUB-09174428

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, 69% of goserelin-pretreated patients versus 35% without preparation reported improved or relieved menstrual cramps.
In plain wordsIn women with menorrhagia, menstrual cramps improved or resolved more often with goserelin pretreatment than no preparation.
Peptide
Goserelin
Outcome
IncreaseImproved or relieved menstrual cramps
Study
n = 60
Comparator
No preoperative preparation
Outcome group
Pain · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Improved or relieved menstrual cramps
69%
pretreated patients (group B + C)
Improved or relieved menstrual cramps
35%
no preoperative preparation (group A)
Source sentences
Summary
Sixty-nine percent of pretreated patients (group B + C) versus 35% of women in group A reported improved or relieved menstrual cramps (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442812
02HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, preoperative goserelin shortened surgery to 32.8 +/- 5.1 minutes versus 46.4 +/- 11.5 minutes without preparation.
In plain wordsIn women with menorrhagia, preoperative goserelin shortened surgery compared with no preparation.
Peptide
Goserelin
Outcome
DecreaseSurgery duration with preoperative dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Surgical outcomes · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Surgery duration, mean
32.8 min
group B, goserelin 4-6 weeks preoperatively
Surgery duration, SD
5.1 min
group B, goserelin 4-6 weeks preoperatively
Surgery duration, mean
46.4 min
group A, no preoperative preparation
Surgery duration, SD
11.5 min
group A, no preoperative preparation
Source sentences
Summary
The duration of surgery for the pretreated group (32.8 +/- 5.1 min) and the group treated postoperatively (30.9 +/- 8.9 min) were significantly shorter than that in the control group (46.4 +/- 11.5 min) (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442801
03HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, preoperative and postoperative goserelin shortened surgery to 30.9 +/- 8.9 minutes versus 46.4 +/- 11.5 minutes without preparation.
In plain wordsIn women with menorrhagia, preoperative and postoperative goserelin shortened surgery compared with no preparation.
Peptide
Goserelin
Outcome
DecreaseSurgery duration with preoperative and postoperative dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Surgical outcomes · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Surgery duration
30.9 min
goserelin before and on the day of resection (group C)
Surgery duration
46.4 min
no preoperative preparation (group A)
Source sentences
Summary
The duration of surgery for the pretreated group (32.8 +/- 5.1 min) and the group treated postoperatively (30.9 +/- 8.9 min) were significantly shorter than that in the control group (46.4 +/- 11.5 min) (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
and C: the same regimen as B, and repeated on the day of endometrial resection.
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442802
04HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, endomyometrial strip weight was about 3 times lower with preoperative goserelin than without preparation.
In plain wordsIn women with menorrhagia, preoperative goserelin reduced endomyometrial strip weight compared with no preparation.
Peptide
Goserelin
Outcome
DecreaseEndomyometrial strip weight with preoperative dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Surgical outcomes · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Endomyometrial strip weight, fold difference
≈ 3 times lower
goserelin group B and C versus group A
Source sentences
Summary
The weight of endomyometrial strips was about 3 times lower for group B and C as compared to group A (p < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442803
05HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, endomyometrial strip weight was about 3 times lower with preoperative and postoperative goserelin than without preparation.
In plain wordsIn women with menorrhagia, preoperative and postoperative goserelin reduced endomyometrial strip weight compared with no preparation.
Peptide
Goserelin
Outcome
DecreaseEndomyometrial strip weight with preoperative and postoperative dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Surgical outcomes · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Endomyometrial strip weight, fold difference
≈ 3 times lower
goserelin group B and C versus group A
Source sentences
Summary
The weight of endomyometrial strips was about 3 times lower for group B and C as compared to group A (p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
and C: the same regimen as B, and repeated on the day of endometrial resection.
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442804
06HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, amenorrhea or scanty bleeding at 3 months occurred in 58% with preoperative goserelin versus twenty five percent without preparation.
In plain wordsIn women with menorrhagia, preoperative goserelin increased amenorrhea or scanty bleeding at 3 months compared with no preparation.
Peptide
Goserelin
Outcome
IncreaseAmenorrhea or scanty bleeding at 3 months with preoperative dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Menstrual Bleeding · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Amenorrhea or scanty bleeding at 3 months
58%
goserelin preoperative (group B)
Amenorrhea or scanty bleeding at 3 months
25%
no preoperative preparation (group A)
Source sentences
Summary
Three months following the procedure twenty five percent of patients in group A were amenorrheic or showed scanty bleeding as compared to 58% and 85% in group B and C (p < 0.05 and p < 0.01), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442805
07HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, amenorrhea or scanty bleeding at 3 months occurred in 85% with preoperative and postoperative goserelin versus twenty five percent without preparation.
In plain wordsIn women with menorrhagia, preoperative and postoperative goserelin increased amenorrhea or scanty bleeding at 3 months compared with no preparation.
Peptide
Goserelin
Outcome
IncreaseAmenorrhea or scanty bleeding at 3 months with preoperative and postoperative dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Menstrual Bleeding · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Amenorrhea or scanty bleeding at 3 months
85%
goserelin before and on the day of resection (group C)
Amenorrhea or scanty bleeding at 3 months
25%
no preoperative preparation (group A)
Source sentences
Summary
Three months following the procedure twenty five percent of patients in group A were amenorrheic or showed scanty bleeding as compared to 58% and 85% in group B and C (p < 0.05 and p < 0.01), respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
and C: the same regimen as B, and repeated on the day of endometrial resection.
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442806
08HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, 12-month amenorrhea or scanty bleeding rates were 58% with preoperative goserelin versus 35% without preparation, without significant difference.
In plain wordsIn women with menorrhagia, 12-month amenorrhea or scanty bleeding did not differ significantly between preoperative goserelin and no preparation.
Peptide
Goserelin
Outcome
No significant changeAmenorrhea or scanty bleeding at 12 months with preoperative dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Menstrual Bleeding · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Amenorrhea or scanty bleeding at 12 months
58%
goserelin preoperative (group B)
Amenorrhea or scanty bleeding at 12 months
35%
no preoperative preparation (group A)
Source sentences
Summary
At 12 months follow-up these rates were 35%, 58% and 67% respectively (A versus B: NS, A versus C: p < 0.05) and 24%, 65% and 75% after excluding larger submucosal fibroids (A versus B: p < 0.025, A versus C: p < 0.005).
2 context sentences(design, population, supporting numbers)
Summary · context
Three months following the procedure twenty five percent of patients in group A were amenorrheic or showed scanty bleeding as compared to 58% and 85% in group B and C (p < 0.05 and p < 0.01), respectively.
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442807
09HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, 12-month amenorrhea or scanty bleeding rates were 67% with preoperative and postoperative goserelin versus 35% without preparation.
In plain wordsIn women with menorrhagia, preoperative and postoperative goserelin increased amenorrhea or scanty bleeding at 12 months compared with no preparation.
Peptide
Goserelin
Outcome
IncreaseAmenorrhea or scanty bleeding at 12 months with preoperative and postoperative dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Menstrual Bleeding · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Amenorrhea or scanty bleeding at 12 months
67%
goserelin before and on the day of resection (group C)
Amenorrhea or scanty bleeding at 12 months
35%
no preoperative preparation (group A)
Source sentences
Summary
At 12 months follow-up these rates were 35%, 58% and 67% respectively (A versus B: NS, A versus C: p < 0.05) and 24%, 65% and 75% after excluding larger submucosal fibroids (A versus B: p < 0.025, A versus C: p < 0.005).
3 context sentences(design, population, supporting numbers)
Summary · context
Three months following the procedure twenty five percent of patients in group A were amenorrheic or showed scanty bleeding as compared to 58% and 85% in group B and C (p < 0.05 and p < 0.01), respectively.
Summary · context
and C: the same regimen as B, and repeated on the day of endometrial resection.
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442808
10HumanRandomized controlled trialEfficacy outcome
In women excluding larger submucosal fibroids, 12-month amenorrhea or scanty bleeding rates were 65% with preoperative goserelin versus 24% without preparation.
In plain wordsIn women excluding larger submucosal fibroids, preoperative goserelin increased amenorrhea or scanty bleeding at 12 months compared with no preparation.
Peptide
Goserelin
Outcome
Increase12-month bleeding response excluding larger submucosal fibroids with preoperative dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Menstrual Bleeding · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Amenorrhea or scanty bleeding at 12 months, excluding larger submucosal fibroids
65%
goserelin preoperative (group B)
Amenorrhea or scanty bleeding at 12 months, excluding larger submucosal fibroids
24%
no preoperative preparation (group A)
Source sentences
Summary
At 12 months follow-up these rates were 35%, 58% and 67% respectively (A versus B: NS, A versus C: p < 0.05) and 24%, 65% and 75% after excluding larger submucosal fibroids (A versus B: p < 0.025, A versus C: p < 0.005).
2 context sentences(design, population, supporting numbers)
Summary · context
Three months following the procedure twenty five percent of patients in group A were amenorrheic or showed scanty bleeding as compared to 58% and 85% in group B and C (p < 0.05 and p < 0.01), respectively.
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442809
11HumanRandomized controlled trialEfficacy outcome
In women excluding larger submucosal fibroids, 12-month amenorrhea or scanty bleeding rates were 75% with preoperative and postoperative goserelin versus 24% without preparation.
In plain wordsIn women excluding larger submucosal fibroids, repeated goserelin increased amenorrhea or scanty bleeding at 12 months compared with no preparation.
Peptide
Goserelin
Outcome
Increase12-month bleeding response excluding larger submucosal fibroids with repeated dosing
Study
n: not reported in source
Comparator
No preoperative preparation
Outcome group
Menstrual Bleeding · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Measurements
Amenorrhea or scanty bleeding at 12 months, excluding larger submucosal fibroids
75%
goserelin before and on the day of resection (group C)
Amenorrhea or scanty bleeding at 12 months, excluding larger submucosal fibroids
24%
no preoperative preparation (group A)
Source sentences
Summary
At 12 months follow-up these rates were 35%, 58% and 67% respectively (A versus B: NS, A versus C: p < 0.05) and 24%, 65% and 75% after excluding larger submucosal fibroids (A versus B: p < 0.025, A versus C: p < 0.005).
3 context sentences(design, population, supporting numbers)
Summary · context
Three months following the procedure twenty five percent of patients in group A were amenorrheic or showed scanty bleeding as compared to 58% and 85% in group B and C (p < 0.05 and p < 0.01), respectively.
Summary · context
and C: the same regimen as B, and repeated on the day of endometrial resection.
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442810
12HumanRandomized controlled trialEfficacy outcome
In women with menorrhagia, no statistical difference was demonstrated between preoperative goserelin and repeated goserelin dosing.
In plain wordsIn women with menorrhagia, no statistical difference was demonstrated between preoperative goserelin and repeated goserelin dosing.
Peptide
Goserelin
Outcome
No significant changeGroup B versus group C difference (outcome not specified)
Study
n: not reported in source
Comparator
Preoperative and postoperative goserelin
Outcome group
Unspecified Outcome · Reproductive and sexual health
Studied dose
3.6 mg · subcutaneous implantAs given in this study (human).
Source sentences
Summary
No statistical difference was demonstrated between group B and C.
2 context sentences(design, population, supporting numbers)
Summary · context
and C: the same regimen as B, and repeated on the day of endometrial resection.
Summary · context
Sixty women with menorrhagia were randomly divided between three groups: A: no preoperative preparation, B: goserelin 3.6 mg given as a subcutaneous implant 4-6 weeks preoperatively
Report a problemFND-0917442811

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.